MEGGLE Excipients & Technology is a manufacturer of lactose for the pharmaceutical industry. With manufacturing facilities in Europe and US, MEGGLE offers a broad product portfolio of lactose excipients.
MEGGLE Excipients & Technology is a global leader in the manufacture of lactose for the pharmaceutical industry. Supporting supply chain security with manufacturing facilities in Europe and North America, MEGGLE offers a broad product portfolio of lactose excipients, co-processed technologies and excipient contract manufacturing.
MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture. Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage forms.
As a family owned, German company, MEGGLE has proudly produced quality products for consumers and industry for four generations.
MEGGLE Excipients & Technologies serves the pharmaceutical and biotechnology markets with a global network of offices and authorized agents. As an innovator in co-processed technology, MEGGLE also provides contract manufacturing services to several other global excipient companies.
Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner by large and small pharmaceutical product manufacturers.
MEGGLE Excipients & Technologies excipient products:
Company name: Molkerei MEGGLE Wasserburg GmbH & Co. KG
Website: www.meggle-pharma.deE-mail: service.pharma@meggle.de
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.